Osimertinib

  • PDF / 169,313 Bytes
  • 1 Pages / 595.245 x 841.846 pts (A4) Page_size
  • 35 Downloads / 135 Views

DOWNLOAD

REPORT


1 S

Lack of efficacy in lung adenocarcinoma: case report A 48-year-old woman exhibited lack of efficacy during treatment with osimertinib for EGFR exon 20 insertion-positive stage-IVB lung adenocarcinoma. The woman was referred to a hospital for chronic cough. Further evaluation showed a nodule in the right middle lobe, consolidation in the right upper lobe, multiple lymph node metastases, liver metastasis and multiple bone metastases. A diagnosis of EGFR exon 20 insertion-positive stage-IVB lung adenocarcinoma was confirmed. Hence, she started receiving oral osimertinib 80 mg/day. There were no adverse events on osimertinib therapy. Her disease remained stable for 2.5 months. Three months later, the tumor started to grow, and carcinoembryonic antigen levels elevated. The disease progression indicated no response to osimertinib therapy. Hence, her treatment was switched to carboplatin, pemetrexed and bevacizumab with a good response. There was an increase in ALT, AST and alkaline phosphatase levels [aetiologies not stated]. Thereafter, her disease remained stable. Inagaki Y, et al. Poor effect of osimertinib on EGFR exon 20 insertion-positive lung adenocarcinoma: A case report. Medicine 99: No. 42, 16 Oct 2020. Available from: URL: 803517404 http://doi.org/10.1097/MD.0000000000022628

0114-9954/20/1832-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved

Reactions 28 Nov 2020 No. 1832